Longevity and disease insights now in 20/20 BioLabs blood test
20/20 BioLabs launched OneTest for Longevity, a consumer blood-based platform that combines biomarkers, lifestyle data and IBM’s watsonx.ai to deliver explainable, personalized aging and chronic-disease risk insights; the test is a laboratory-developed test (not FDA-approved), built in partnership with DAISource, and follows the company’s Nasdaq listing under ticker AIDX.
Why it mattersFollowing 20/20 BioLabs' February 19 Nasdaq debut, OneTest's launch may prompt earlier inflammation-targeting lifestyle changes.
Entities Mentioned
20/20 BioLabsDAISourceNasdaq
People Mentioned
Kyle Umipig